Bioinformatics Analysis and Experimental Verification Identify Downregulation of COL27A1 in Poor Segmental Congenital

Zongshan Hu1, Yanjie Xu1, Jie Li1

  • 1Division of Spine Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.

Insights

This study identified COL27A1 as a key biomarker for poor segmental congenital scoliosis (PSCS) progression. Downregulation of COL27A1 in PSCS patients suggests it as a potential therapeutic target for this spinal deformity.

Area of Science:

  • Genetics and Bioinformatics
  • Developmental Biology
  • Orthopedics

Background:

  • Congenital scoliosis (CS) is a birth defect with poor segmental congenital scoliosis (PSCS) as a subtype.
  • Delayed intervention for PSCS can lead to severe disability and paralysis.

Purpose of the Study:

  • To identify core biomarkers for PSCS progression using bioinformatics and experimental verification.
  • To elucidate the pathogenic mechanism of PSCS and identify potential therapeutic targets.

Main Methods:

  • Utilized GEO database (GSE11854) for somite formation gene expression data.
  • Employed R packages (edgeR, clusterProfiler, DESeq2) for differential gene expression (DEG) analysis, GO/KEGG/DO annotation, and LASSO regression.
  • Performed RNA sequencing on peripheral blood samples from healthy donors and PSCS patients.
  • Validated COL27A1 expression using RT-PCR assay.

Main Results:

  • Identified 443 DEGs related to somite formation, enriched in TGF-β signaling pathway and spinal deformity.
  • LASSO regression identified 9 DEGs as signature markers for somite formation.
  • Discovered 162 DEGs in PSCS patients, associated with cardiac myofibril assembly and muscle structure.
  • COL27A1 was the sole intersecting gene between somite formation predictors and PSCS DEGs, found to be significantly downregulated in PSCS patients.

Conclusions:

  • Novel differentially expressed genes (DEGs) related to PSCS pathogenesis were identified.
  • COL27A1 is a potential therapeutic target for PSCS.
  • Findings may aid in developing therapeutic strategies for PSCS.
Abstract

Related Concept Videos